Ryuji Maekawa

Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):  <i>N</i>-Sulfonylamino Acid Derivatives

Yoshinori Tamura, Fumihiko Watanabe, Takuji Nakatani et al. · Journal of Medicinal Chemistry · 1998 · 283 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.

Takayuki Yoshioka, Tsutomu Wada, Naoshige Uchida et al. · PubMed · 1998 · 147 citations

Medicine, Oncology, Pharmacology +13

Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest

Hirokazu Matsushita, Akihiro Hosoi, Satoshi Ueha et al. · Cancer Immunology Research · 2014 · 109 citations · Full text

Life Sciences, Immunology, Oncology +17

Restricted V-segment usage in T-cell receptors from cytotoxic T lymphocytes specific for a major epitope of lymphocytic choriomeningitis virus

Yusuke Yanagi, Ryuji Maekawa, T Cook et al. · Journal of Virology · 1990 · 61 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.

Ryuji Maekawa, Hideo Maki, Hitoshi Yoshida et al. · PubMed · 1999 · 59 citations

Medicine, Oncology, Pharmacology +10